

ECCMID 2021 (1) #01616

Activity of Oritavancin and Comparators against a Contemporary Collection of *Enterococcus* spp. Clinical Isolates from Europe (2015-2019)

Cecilia G. Carvalhaes; Helio S. Sader; Jennifer M. Streit; Mariana Castanheira; Rodrigo E. Mendes



_ 3,567



• E. faecalis ($2,1$ 2) E. faecium ($1,304)$, $\boxed{}$
- 1.6% - E. faecium (п. 1.).
- , , , (13. %) , (1.1%).
-E. faecium (1) — — — — — — — — — — — — — — — — — — —
2 (10.5%) E. faecalis (щ 1.).
4 E. faecium (1 .1% щ 1,)
E. faecalis ((50/ o') (11/1) (1 2).
· E. faecalis
(100%), (100%)
H. 100.0% - 1
() — — (2) E. faecalis —
E. faecium $0.004/0.015$
5% - 5% - (4) E. faecium - (4)
- k. (2. %) (100% (100%
E. faecium (H 3).
100.0% - (2)
TUU.U701- "

Table 1. Participant countries and the respective occurrence of VRE phenotypes in each European region

Participant country by region	Total no. of isolates contributed	VRE phenotype	
		VanA	VanB
W-EU			
•	15	2	1
Ш,	364		1
F	63	13	3
L	201	4	
	6	64	12
	154	4	2
	3	1	
,	1 2	1	
, . –	5		
1 .	21	20	2
E-EU			
F ,	1	2	2
L J^	22	1	3
	24		4
		3	
_ 4	160	11	4

Table 2. Antimicrobial act oritavancin and comparate tested against E. faecalis from European hospitals.





H (201). 0 - 11. (2020) 2503. 4 2005 5 1064 3. (1), The second of the second 2015 0 21 2 0.



